

GRAYCARY

4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133
www.graycary.com

O] 858-677-1456
F] 858-677-1465

FAX TRANSMISSION COVER SHEET

July 12, 2004

To:
Janet Higgins
U.S. Patent and Trademark Office
Patent Publication Office

Telephone:
703-308-6187

Fax Number:
703-746-4625

From: Lisa A. Halle, J.D., Ph.D.
858-677-1456

Client-Matter Number: 104703-160131

Re: U.S. Patent Application No. 09/529,458
Attorney Docket No. DIVER1380-1

Pages: - 44 - (including this form) **Originals:** ☐ will be mailed ☒ will not be mailed

If there is a problem with this transmission, please call (858) 638-6633 (Greg Austin)

Message:

Dear Ms. Higgins,

In response to your voice-mail request, attached please find a copy of the Response filed August 20, 2001 for the above-identified application.

Please let us know if you need anything else.

Thank you.

CONFIDENTIALITY NOTICE

This communication is ONLY for the person named above. Unless otherwise indicated, it contains information that is confidential, privileged or exempt from disclosure under applicable law. If you are not the person named above, or responsible for delivering it to that person, be aware that disclosure, copying, distribution or use of this communication is strictly PROHIBITED. If you have received it in error, or are uncertain as to its proper handling, please immediately notify us by collect telephone and mail the original to us at the above address. Thank you.

(Form Rev. 6/5/00)

Gray Cary\GT\6407097.1
104703-160131

PATENT
Attorney Docket No.: DIVER1380-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jay M. Short Art Unit: 1636
Application No.: 09/529,458 Examiner: B. Loeb
Filed: May 23, 2000
Title: SCREENING FOR NOVEL COMPOUNDS WHICH REGULATE
BIOLOGICAL INTERACTIONS

Commissioner for Patents
Washington, D.C. 20231

RESPONSE

Sir:

This revised response is filed in response to the Notice of Non-Compliant Amendment (Paper number 14). As set forth below, the Response is now in compliance with 37 C.F.R. 1.121(b)(1)(ii) and 37 C.F.R. 1.121(b)(1)(iii). The Response was originally filed in response to the Office Action dated November 8, 2000 (Paper number 8). Entry of the amendments and reconsideration of the application in view of the following is respectfully requested.

IN THE SPECIFICATION:

Please insert the attached sequence listing into the present specification.

Please insert the following replacement paragraphs:

Please replace the original paragraph at page 1, lines 16-27 with the following paragraph:

Within the last decade there has been a dramatic increase in the need for bioactive compounds with novel activities. This demand has arisen largely from changes in worldwide demographics coupled with the clear and increasing trend in the number of pathogenic organisms that are resistant to currently available antibiotics. For example, while there has been a surge in

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on August 17, 2001, in an envelope addressed to:
Commissioner for Patents, Washington, D.C. 20231

Karen DePari
Karen LePari